We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202

News   Dec 06, 2012

 
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
 
 
 

RELATED ARTICLES

Fire, Sun or Electricity Powers Hand-held Cancer Detection Device

News

Device shows promise as a point-of-care detector of Kaposi sarcoma-associated herpesvirus in resource-limited settings.

READ MORE

Ovarian Cancer Biomarker Can Predict Patient Therapy Response

News

Researchers have identified an independent prognostic factor - cancer/testis antigen 45 (CT45) - and have begun to elucidate it's actions. CT45 is associated with extended disease-free survival for women with advanced ovarian cancer.

READ MORE

Cancer Immunotherapy Might Benefit From Previously Overlooked Immune Players

News

Genetic data highlights the previously understated role CD4+ T cells and MHC-II molecules play in keeping cancer at bay.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE